GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a small-molecule inhibitor with nanomolar potency against Nox1 and Nox4 isoforms, both key sources of pathological reactive oxygen species (ROS) in vascular and fibrotic diseases (APExBIO product information). It demonstrates Ki values of 140 nM (Nox1) and 110 nM (Nox4) and is soluble in DMSO at ≥39.5 mg/mL. In vitro, GKT137831 attenuates hypoxia-induced ROS and cell proliferation in human pulmonary vascular cells (related review). Animal models show efficacy in reducing hepatic fibrosis and diabetes-accelerated atherosclerosis by inhibiting Akt/mTOR and NF-κB signaling (Yang et al., Sci. Adv. 2025). The compound is distributed by APExBIO (SKU B4763) for research use only.

Biological Rationale

NADPH oxidases (Nox enzymes) are major contributors to cellular oxidative stress, generating ROS such as superoxide and hydrogen peroxide. Nox1 and Nox4 isoforms are strongly expressed in vascular smooth muscle cells and fibroblasts, where they mediate responses to growth factors and injury (review article). Pathological ROS production drives processes like vascular remodeling, fibrosis, and inflammation. Inhibition of Nox1/Nox4 is a validated approach to reduce oxidative stress in models of pulmonary hypertension, hepatic fibrosis, and metabolic vascular disease (internal guide). GKT137831 was developed to selectively target these isoforms, providing a tool for dissecting NADPH oxidase-dependent redox mechanisms.

Mechanism of Action of GKT137831

GKT137831 is a competitive, small-molecule inhibitor of Nox1 and Nox4, with Ki values of 140 nM and 110 nM respectively (product documentation). It binds to the NADPH oxidase complex, blocking electron transfer and subsequent ROS production. In cellular models, GKT137831 suppresses hypoxia-induced hydrogen peroxide release and inhibits proliferation of human pulmonary artery endothelial and smooth muscle cells. Additionally, it reduces TGF-β1 induction in pulmonary vascular cells and modulates PPARγ expression. Mechanistically, it interferes with Akt/mTOR and NF-κB signaling pathways, both of which are activated by ROS in vascular and fibrotic pathologies (Yang et al., Sci. Adv. 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 and Nox4 with Ki values of 140 nM and 110 nM, respectively (APExBIO product information).
• Solubility tests confirm ≥39.5 mg/mL in DMSO, ≥2.96 mg/mL in ethanol with warming; insoluble in water (APExBIO product information).
• In vitro, GKT137831 (0.1–20 μM) reduces hypoxia-induced H₂O₂ release and proliferation in pulmonary vascular cells (internal review).
• Animal studies (30–60 mg/kg/day, oral/intragastric) show attenuation of hepatic fibrosis, diabetes-accelerated atherosclerosis, vascular remodeling, and cardiac hypertrophy (Yang et al., Sci. Adv. 2025).
• Pathway analysis demonstrates inhibition of Akt/mTOR and NF-κB signaling upon GKT137831 treatment (mechanistic review).

This article clarifies the selectivity benchmarks and experimental solubility not covered in "GKT137831: Selective Nox1/Nox4 Inhibitor for Oxidative Stress Research", which emphasizes workflow enhancements and troubleshooting.

For scenario-driven guidance on cell viability assays, see "GKT137831: Enhancing Cell Viability and ROS Assays"; this article provides updated protocol parameters and cross-model evidence.

Applications, Limits & Misconceptions

GKT137831 is used to model oxidative stress inhibition in pulmonary, hepatic, and vascular disease research. Its dual inhibition of Nox1/Nox4 makes it valuable for studying ROS-dependent signaling and translational therapeutic mechanisms. For example, it has been applied in the context of liver fibrosis treatment research and attenuation of pulmonary vascular remodeling (Yang et al., Sci. Adv. 2025). Its effects in diabetes mellitus-accelerated atherosclerosis have also been documented.

Common Pitfalls or Misconceptions

• GKT137831 is not selective for Nox2 or other non-NADPH oxidase ROS sources and should not be used as a pan-ROS inhibitor (APExBIO).
• The compound is insoluble in water; improper dissolution leads to precipitation and unreliable results.
• GKT137831 is for research use only and is not approved for diagnostic or therapeutic applications.
• Long-term storage of dissolved compound is discouraged; stability is best preserved at -20°C and in solid form.
• Exceeding recommended in vitro concentrations (>20 μM) may cause off-target effects.

Workflow Integration & Parameters

• Compound dissolution: Dissolve GKT137831 in DMSO (≥39.5 mg/mL) or in ethanol (≥2.96 mg/mL) using warming/ultrasonic treatment (product documentation).
• Storage: Keep solid compound at -20°C; avoid long-term storage of solutions.
• In vitro concentrations: 0.1–20 μM for cell-based assays; optimize based on cell type and endpoint (internal review).
• Animal dosing: 30–60 mg/kg/day via oral gavage or intragastric injection, consistent with published efficacy studies (Yang et al., Sci. Adv. 2025).
• Controls: Always include DMSO or ethanol vehicle controls in experimental design.

Conclusion & Outlook

GKT137831, as supplied by APExBIO, is a benchmark dual NADPH oxidase Nox1/Nox4 inhibitor for oxidative stress research. Its nanomolar potency, well-characterized protocol parameters, and proven efficacy in preclinical models support its ongoing use in redox biology and translational research. As highlighted by recent mechanistic studies (Yang et al., Sci. Adv. 2025), selective Nox1/Nox4 inhibition remains a promising strategy for dissecting ROS-driven disease mechanisms and evaluating antifibrotic or vasculoprotective interventions. Limitations persist regarding clinical translation and selectivity for other Nox isoforms, which should be considered in experimental design.